



Charles F. Wagner

Executive Vice President and Chief Financial Officer

Charles (Charlie) Wagner joined Vertex Pharmaceuticals in 2019 as Executive Vice President and Chief Financial Officer (CFO). In this role, Mr. Wagner oversees the accounting, finance, internal audit, investor relations, business development transactions and alliance management, and global security and facilities functions. Mr. Wagner has deep corporate finance and health care experience, including more than a decade in public and private company CFO roles.

Prior to joining Vertex, Mr. Wagner was Executive Vice President, Finance and CFO at Ortho Clinical Diagnostics — a Carlyle Group portfolio company. In this role, he had leadership responsibilities for all aspects of finance, accounting, tax, treasury, global financial systems, lender relations, and acquisitions and divestitures, as well as shared responsibility for several enterprise-wide projects. Prior to this, Mr. Wagner served as CFO for Bruker Corporation, Progress Software Corporation and Millipore Corporation. In addition to his corporate finance roles, Mr. Wagner served as an advisor at Bain & Company and Coopers & Lybrand.

Mr. Wagner serves on the board of directors for The TJX Companies, Inc. and is a member of its Audit and Finance Committee. From April 2014 to August 2017, he served as a director and chairman of the Audit Committee of Good Start Genetics. He also served as a director of Bruker Corporation and a member of the Audit Committee from August 2010 to June 2012. Mr. Wagner holds a B.S. in accounting from Boston College and an M.B.A. from Harvard Business School.

Contact:

Charles F. Wagner

Executive Vice President and Chief
Financial Officer
he/him/his

Vertex Pharmaceuticals Incorporated
50 Northern Avenue
Boston, MA 02210
+1 (617) 341-6100
vrtx.com

Joined Vertex: 2019

Education:

Boston College
Harvard University